Discovery of (1<i>S</i>,2<i>R</i>,3<i>S</i>,4<i>S</i>,5<i>R</i>,6<i>R</i>)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity
作者:Mark D. Chappell、Renhua Li、Stephon C. Smith、Bruce A. Dressman、Eric G. Tromiczak、Allie E. Tripp、Maria-Jesus Blanco、Tatiana Vetman、Steven J. Quimby、James Matt、Thomas C. Britton、Adam M. Fivush、Jeffrey M. Schkeryantz、Daniel Mayhugh、Jon A. Erickson、Mark G. Bures、Carlos Jaramillo、Mercedes Carpintero、José Eugenio de Diego、Mario Barberis、Susana Garcia-Cerrada、José F. Soriano、Stephen Antonysamy、Shane Atwell、Iain MacEwan、Bradley Condon、Christine Sougias、Jing Wang、Aiping Zhang、Kris Conners、Chris Groshong、Stephen R. Wasserman、John W. Koss、Jeffrey M. Witkin、Xia Li、Carl Overshiner、Keith A. Wafford、Wesley Seidel、Xu-Shan Wang、Beverly A. Heinz、Steven Swanson、John T. Catlow、David W. Bedwell、James A. Monn、Charles H. Mitch、Paul L. Ornstein
DOI:10.1021/acs.jmedchem.6b01119
日期:2016.12.22
-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride (LY3020371·HCl, 19f), a potent, selective, and maximally efficacious mGlu2/3 antagonist. Further characterization of compound 19f binding to the human metabotropic 2 glutamate (hmGlu2) site was established by cocrystallization of this molecule with the amino terminal domain (ATD) of the hmGlu2 receptor protein. The resulting cocrystal structure
作为我们为代谢型谷氨酸2和3(mGlu 2/3)受体鉴定新配体的工作的一部分,我们在(1 S,2 R,5 R,6 R)的C3和C4位置引入了取代基-2-氨基-双环[3.1.0]己烷-2,6-二羧酸支架产生mGlu 2/3拮抗剂。对这种结构-活性关系(SAR)的探索导致了对(1 S,2 R,3 S,4 S,5 R,6 R)-2-氨基-3-[(3,4-二氟苯基)硫烷基甲基的鉴定] -4-羟基-双环[3.1.0]己烷-2,6-二羧酸盐酸盐(LY3020371·HCl,19f),一种有效,选择性和最大效力的mGlu 2/3拮抗剂。通过将该分子与hmGlu 2受体蛋白的氨基末端结构域(ATD)共结晶,可以确定与人代谢型2谷氨酸(hmGlu 2)位点结合的化合物19f的进一步表征。由此产生的共晶体结构揭示了特定的配体-蛋白质相互作用,这可能解释了19f对这个位点的高亲和力,并支持其功能性mGlu 2拮